Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 3/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | EDNRA | P25101 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28046229 | 0.87 | CA2 (0.59) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8490327 | 0.82 | CA2 (0.47) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL21955660 | 0.82 | CA2 (0.47) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL21955659 | 0.82 | CA2 (0.47) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27405064 | 0.82 | CA2 (0.44) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27495668 | 0.80 | CA2 (0.64) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5706282 | 0.79 | CA2 (0.52) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3765136 | 0.79 | CA2 (0.49) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL28751226 | 0.78 | F2 (0.56) | CA2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL419154 | 0.78 | TTR (0.42) | NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 384 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378396-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | STEALTH BIOTHERAPEUTICS CORP (MC) | 2014-12-25 | — | — | US | claimed |
| EP-4711005-A2 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | Stealth BioTherapeutics Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TUFTS MEDICAL CENTER, INC. | 2025-09-04 | — | — | US | disclosed |
| US-20250263433-A1 | METHODS FOR REDUCING CD36 EXPRESSION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20070027087-A1 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-01 | — | — | US | disclosed |
| US-20070015711-A1 | Administering aromatic cationic peptide for targeted mitochondria; antiischemic, -inflammatory, -arthritic, -diabetic agents, liver disorders, stroke; sepsis; viricides; organ removal; neurogenerative diseases; Parkingson's,Alzheimer's, Huntington's diseases; amyotrophic lateral sclerosis | CORNELL RESEARCH FOUNDATION, INC. | 2007-01-18 | — | — | US | disclosed |
| EP-1722807-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | Cornell Research Foundation Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060084606-A1 | administering aromatic cationic peptide for specifically target mitochondria; ischemia is due to stroke, sepsis, inflammatory process, arthritis, diabetes, liver disorders, viral infection, to a removed organ | CORNELL RESEARCH FOUNDATION, INC. | 2006-04-20 | — | — | US | disclosed |
| EP-1625149-A2 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1599216-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005072295-A2 | METHODS FOR REDUCING OXIDATIVE DAMAGE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050158373-A1 | Small peptides that are energy-independent, non-endocytotic; nontoxic, peptidase resistant | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | disclosed |
| WO-2005001023-A2 | METHOD AND CARRIER COMPLEXES FOR DELIVERING MOLECULES TO CELLS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004070054-A2 | METHODS FOR PREVENTING MITOCHONDRIAL PERMEABILITY TRANSITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378396-A1 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | PDF, AIFM1, PITRM1 | CA2 2079/4885F2 1845/4885PRSS1 1674/4885 |
| US-20260061023-A1 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF BARTH SYNDROME | ARG2, ARGLU1, BCAT1 | CA2 3372/4885F2 1609/4885PRSS1 637/4885 |
| US-20250255929-A1 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH | TNNI3, TNNT2, FABP3 | CA2 547/4885F2 2783/4885PRSS1 1946/4885 |
| US-20250319152-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | CA2 1016/4885F2 3525/4885PRSS1 1659/4885 |
| US-20260062752-A1 | METHODS AND COMPOSITIONS FOR DETECTING AND DIAGNOSING DISEASES AND CONDITIONS | ARG2, MTPN, TNNT2 | CA2 2610/4885F2 2027/4885PRSS1 1254/4885 |
| US-20250262269-A1 | METHODS FOR PERFORMING A CORONARY ARTERY BYPASS GRAFT PROCEDURE | RNPEP, TNNI3, BDKRB1 | CA2 1498/4885F2 1787/4885PRSS1 162/4885 |
| US-20250276116-A1 | METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION | TNNI3, TNNT2, MB | CA2 215/4885F2 2144/4885PRSS1 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.